Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Glioblastoma
100%
Temozolomide
100%
Long Non-coding RNA (LncRNA)
100%
RNA Mechanisms
100%
Glioma Patients
28%
Non-coding RNA (ncRNA)
14%
RNA Sequencing (RNA-seq)
14%
Glioma Cells
14%
Functional Validation
14%
Response Marker
14%
Tumor Resistance
14%
Innovative Analysis
14%
Genetic Features
14%
New Predictor
14%
Transcriptional Analysis
14%
Surgical Resection
14%
Epigenetics
14%
Molecular Pathways
14%
Clinical Model
14%
Regulatory Circuit
14%
Human Glioblastoma
14%
Role in Cancer
14%
Chemotherapy
14%
Transcriptional Program
14%
Transcriptional Regulatory
14%
Patient Prognosis
14%
Chromatin Dynamics
14%
Chemoresistance
14%
Poor Prognosis
14%
Tumor Recurrence
14%
Aggressive Therapy
14%
Clinical Potential
14%
Functional Role
14%
O6-methylguanine-DNA Methyltransferase
14%
Non-coding
14%
Treatment Strategy
14%
Patient-derived
14%
Novel Molecular Targets
14%
Glioblastoma Cell Line
14%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Long Untranslated RNA
100%
Temozolomide
77%
Malignant Neoplasm
22%
Molecular Target
11%
RNA-Sequencing
11%
Untranslated RNA
11%
6 O Methylguanine
11%
Tumor Recurrence
11%
Tumor Resistance
11%
Drug Resistance
11%
Messenger RNA
11%
Methyltransferase
11%
Chemotherapy Regimens
11%
Glioma
5%
Neuroscience
Temozolomide
100%
Long Non-Coding RNA
100%
In Vivo
28%
RNA Sequence
14%
Non-Coding RNA
14%
Genetics
14%
Chemotherapy
14%
Messenger RNA
14%
6-O-Methylguanine
14%
Cell Line
14%
Glioma
14%
Drug Resistance
14%
Methyltransferase
14%
Chromatin
7%